The document surveys literature on antibody cocktails for treating mild to moderate COVID-19 in high-risk patients. It discusses the authorization of Eli Lilly's and Regeneron-Roche's antibody treatments by federal regulators and highlights a lawsuit against Regeneron over the use of a patented fluorescent protein. Additionally, it mentions a federal lawsuit involving Pfizer and BioNTech related to their COVID-19 vaccine development.

1. Antibody
Cocktail
Literature Survey
Presentation by
Primary Information Services
www.primaryinfo.com
mailto:primaryinfo@gmail.com

2. Antibody cocktail is to be
administered for treatment of mild
to moderate coronavirus disease in
adults and pediatric patients who
are confirmed to be infected with
SARS-COV2 and are at high risk of
developing severe COVID-19
disease and do not require oxygen

5. A combination of two Eli Lilly & Co. antibody-based drugs to
treat recently diagnosed Covid-19 was authorized by federal
health regulators, the latest treatment aimed to help people at
high risk of severe disease from avoiding hospitalization.

13. Regeneron and Roche's antibody cocktail received emergency-use authorization in India

14. The Regeneron Pharmaceuticals Inc. “antibody cocktail was developed with the unauthorized use of
a fluorescent protein, according to a lawsuit by a California company that patented the technology.
• Allele Biotechnology and Pharmaceuticals Inc., a closely held company founded in 1999, sued
Regeneron on Monday in New York seeking royalties for the use of its mNeonGreen protein in
developing the treatment.
• The patent for mNeonGreen, issued in March 2019, covers the use of the protein, which Allele said
scientific journals have dubbed the “gold standard” for testing the efficacy of antibody and
vaccine candidates.
• A separate federal lawsuit was filed in California against Pfizer Inc. and BioNTech SE, partners in
the race to develop a Covid-19 vaccine.

18. Database Contents
offer
Technology, Technology Offers, Production, Projects, Market,
Applications, Company Profiles
https://www.primaryinfo.com/monoclonal-antibodies.htm

19. Database Contents offer
Literature Survey:
Internet Data Base
Information Retrieval
Services
https://www.primaryinfo.com/
antibody.htm